Haratani K, Nakamura A, Mamesaya N, Sawa K, et al. Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer. Br J Cancer 2024 Mar 22. doi: 10.1038/s41416-024-02662.
PMID: 38519705